5 completed, 1 suspended. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Suspended 1 |
Follow ChemomAb Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis 10 mg/kg CM-101, Placebo - Systemic Sclerosis | Phase 2 | Suspended | ChemomAb Ltd. | 45 | 2026-09-01 | 2026-04-15 |
| CM-101 in NASH Patients - The SPLASH Study 5 mg/kg CM-101, Placebo - Nonalcoholic Steatohepatitis | Phase 2 | Completed | ChemomAb Ltd. | 23 | 2021-02-24 | 2023-04-21 |
| CM-101 in PSC Patients -The SPRING Study Anti-human CCL24 monoclonal antibody (CM-101), Placebo - Primary Sclerosing Cholangitis | Phase 2 | Completed | ChemomAb Ltd. | 77 | 2020-10-01 | 2026-07-02 |
| Subcutaneous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects CM-101, Placebo - Nonalcoholic Steatohepatitis (NASH), Primary Sclerosing Cholangitis (PSC) | Phase 1 | Completed | ChemomAb Ltd. | 8 | 2019-03-05 | 2023-09-14 |
| The Study of Multiple Doses of CM-101 in Male and Female NAFLD (Nonalcoholic Fatty Liver Disease) and NAFLD/NASH (Nonalcoholic Steatohepatitis) Subjects Anti-human CCL24 monoclonal antibody (CM-101) - Part One, Anti-human CCL24 monoclonal antibody (CM-101) - Part Two, Placebo - Study Part One - Nonalcoholic Fatty Liver Disease | Phase 1 | Completed | ChemomAb Ltd. | 16 | 2018-12-11 | 2023-09-21 |
| Intravenous Doses of CM-101 as a Treatment for Medical Conditions Involving Inflammatory and Fibrotic Mechanisms in Healthy Male Subjects Anti-human CCL24 monoclonal antibody (CM-101), Placebo - Healthy | Phase 1 | Completed | ChemomAb Ltd. | 32 | 2017-07-24 | 2023-09-11 |
Non-alcoholic Fatty Liver Disease (3) · Cholangitis, Sclerosing (2) · Scleroderma, Systemic (2)
streptococcal polysaccharide type III group B (6)
Israel (5) · United States (2) · Germany (1) · Spain (1) · United Kingdom (1)
Matthew Frankel, MD (3) · Arnon Aharon, MD (2) · Jacob Atsmon, MD (1) · Rifaat Safadi, MD (1)